Press Release
<< Back
Acadia Pharmaceuticals Appoints Elizabeth Garofalo, M.D. to Board of Directors
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201001005364/en/

Dr.
“Dr. Garofalo is a highly-regarded business leader and innovator with invaluable clinical development experience,” said
“I look forward to working with the talented Acadia management team as they continue to seek breakthroughs in the field of CNS, pioneering new research and developing innovative new therapies to address unmet needs,” said
Since 2016,
About
Acadia is trailblazing breakthroughs in neuroscience to elevate life through science. For more than 25 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialize the first and only approved therapy for hallucinations and delusions associated with Parkinson’s disease psychosis. Our late-stage development efforts are focused on dementia-related psychosis, negative symptoms of schizophrenia and Rett syndrome, and in early-stage clinical research we are exploring novel approaches to pain management, and cognition and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at www.acadia-pharm.com and follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201001005364/en/
Media Contact:
(858) 914-7161
media@acadia-pharm.com
Investor Contact:
(858) 261-2771
ir@acadia-pharm.com
Source: